The six biotech companies in Portugal you should know about in 2026

The six biotech companies in Portugal you should know about in 2026 By Willow Shah-Neville 8 minutesmins March 23, 2026 8 minutesmins Share WhatsApp Twitter Linkedin Email Photo credits: Aayush Gupta Newsletter Signup - Under Article / In Page"*" indicates required fieldsNameThis field is for validation purposes and should be left unchanged.Subscribe to our newsletter to get the latest biotech news!By clicking this I agree to receive Labiotech's newsletter and understand that my personal data will be processed according to the Privacy Policy.*Company name*Job title*Business email* Portugal’s biotech ecosystem may be small, but it is steadily on the rise. The life sciences industry in the country is particularly strong in the area of medical biotech and is supported by the presence of Bial, the largest pharmaceutical company in the country, with headquarters in the Porto area. For the first time ever, BIO-Europe Spring will take place in Lisbon from 23 to 25 March, reinforcing Portugal’s position as a credible and innovative hub for biotech investment. As the event kicks off today, we thought we would look at six biotech companies driving innovation in the host nation.Table of contentsBeat Therapeutics Location: PortoTechnology: DDR inhibitorsLead candidate: Asset for pancreatic cancerFounded in 2023 as a University of Porto spin-off, Beat Therapeutics’ mission is to pioneer more effective therapeutic options for patients facing hard-to-treat, aggressive cancers. To do so, it exploits genomic instability – one of cancer’s defining traits – and is working on a new class of precision therapies that turn “genomic chaos” into therapeutic control, delivering targeted treatments to patients. More specifically, the company leverages DNA damage response (DDR), a complex, chromatin-associated signaling network that senses DNA damage, triggers cell cycle checkpoints, and initiates repairs to maintain genomic integrity. Its DDR inhibition approach targets homologous recombination, in turn disrupting DNA repair mechanisms in cancer cells – a targeted strategy that can maximize therapeutic efficacy while minimizing off-target effects on healthy tissues. According to venture capital firm Portugal Ventures, the Portuguese company’s lead candidate targets pancreatic cancer as a clinical priority and has demonstrated high therapeutic efficacy in preclinical assays.In 2023, Beat Therapeutics secured the top position in the Bio/Pharmatech category at the Startup Olé pitching event, one of Europe’s leading startup events. BSIM TherapeuticsLocation: CoimbraTechnology: Transthyretin stabilizersLead candidate: Asset for transthyretin amyloidosisFounded as an academic spinoff based on research from the University of Coimbra conducted in collaboration with the University of Leeds, BSIM Therapeutics uses molecular modeling, cheminformatics, data mining, and machine learning to develop new drugs for a rare disease called transthyretin amyloidosis. This disease is caused by a mutation that leads the protein transthyretin to build up, causing progressive degeneration of multiple organs and tissues. BSIM’s most advanced drug candidate, currently undergoing preclinical testing, is a potent stabilizer of the transthyretin protein that aims to slow down the progression of symptoms affecting the heart. The company also has two other stabilizer candidates in the optimization phase, targeting symptoms affecting the brain and the eye. According to Portugal Ventures, the quality and validity of BSIM Therapeutics’ strategy has seen several applications submitted to Community funds (QREN and Portugal2020) approved, and it has also attracted different investors, among them Portugal Ventures, A2B SGPS (a business angel), and Bluepharma (a pharmaceutical company).Exogenus TherapeuticsLocation: CantanhedeTechnology: Exosome therapeuticsLead candidate: Exo-101 for chronic woundsExogenus Therapeutics was founded to develop therapies based on a technology conceived at the University of Coimbra that relies on extracellular vesicles and exosomes – molecular vehicles that cells use to transport molecules across the body. The company’s lead candidate, Exo-101, which is derived from umbilical cord blood cells, has shown regenerative and anti-inflammatory properties in preclinical trials and is being explored for the treatment of chronic wounds that do not respond to conventional treatments, as well as inflammatory diseases affecting the skin and lungs. Its multifactorial mode-of-action, mediated by a cocktail of small RNAs, proteins, and anti-inflammatory lipids, provides the foundation for the drug’s therapeutic potential and positive safety profile. Suggested Articles Watch: Biocant Park – a biotech hub in the heart of Portugal 10 biotech companies you should know about in Spain The rise of Spain: A key player in global clinical trials Pushing biotech forward in France: 18 companies to know about Eight biotech companies tackling infectious diseases head-on The Portugal-based biotech company partnered with Boehringer Ingelheim in 2022 to explore Exo-101 for regenerative medicine applications. More recently, the company also partnered with Lonza, whereby Lonza is leveraging its expertise in exosome development and analytical services and dedicating a team of experts to define a GMP-compliant process for Exo-101 production. The asset is expected to reach patients in 2027. In April 2024, Exogenus announced that it had secured an undisclosed amount of funding to help the company advance the development of Exo-101. ImmunethepLocation: CantanhedeTechnology: Vaccines and monoclonal antibodies Lead candidate: PNV_Ent for Escherichia coli and Klebsiella pneumoniae infectionsA spin-off from the University of Porto in northwest Portugal, Immunethep is an infectious disease biotech company and is primarily focused on fighting the spread of antibiotic resistance by developing antibacterial immunotherapies. The company has been involved in the discovery of a virulence mechanism that is highly immunosuppressive and is shared by different bacteria. The mechanism involves the excretion of a protein called glyceraldehyde-3-phosphate dehydrogenase (GAPDH) by bacteria that essentially shuts down the host’s immune system. The company’s research and development work is focused on the different steps of this mechanism and how to block it in a way that the immune system is able to respond to the infection. Immunethep has developed the “Paragon Novel Vaccine (PNV)” concept – a product line of vaccines providing effective protection against bacterial infections caused by multiple bacteria. PNV, a peptide-based immunotherapy, works by neutralising an extracellular form of bacterial GAPDH, without blocking the human GAPDH. This enables the host immune system to fight the infection and eliminate the bacteria. According to the company’s website, preclinical trials performed on animal models have demonstrated high levels of efficacy against the bacteria with a strong safety profile. Its lead candidate from its PNV product line is called PNV_Ent, which is designed to address Escherichia coli and Klebsiella pneumoniae. In February 2025, the Portugal-based biotech company was awarded $2 million in funding from CARB-X to support the development of its vaccine against invasive E.coli infections. Then, in April, Immunethep was also awarded £1 million ($1.3 million) in funding from PACE to advance monoclonal antibodies that restore the ability to control bacterial infections without inducing antimicrobial resistance. According to the company’s website, it has established collaborations along the way with Merck & Co. (MSD), Merck Animal Health, GSK, and Vetoquinol. Mondego BioLocation: CantanhedeTechnology: PTPN2 inhibitorsLead candidate: ZE00-0388 for cancerMondego Bio is developing best-in-class protein tyrosine phosphatase non-receptor type 2 (PTPN2) inhibitors with an aim of providing a potential immuno-oncological therapy with an improved safety and tolerability profile. As a critical negative regulator of the JAK-STAT pathway, PTPN2 directly regulates signaling through cytokine receptors, including IFNγ. Therefore, enhancing IFNγ sensing and signaling through the inhibition of PTPN2 is a potential therapeutic strategy to improve the efficacy of cancer immunotherapy regimens.In July 2025, the company presented promising preclinical data for its candidate, ZE00-0388, showing that the asset demonstrated strong oral bioavailability and significant efficacy when combined with anti–mPD-1 therapy in subcutaneous MC38 colon cancer models in female C57BL/6 mice. The combination therapy not only halted tumor growth but also induced complete and sustained tumor regression, even after discontinuation of anti–mPD-1 treatment. Subsequently, in December, Mondego Bio decided to formally select ZE00-0388 as its lead candidate. With this milestone, the company said it would be transitioning into clinical-stage operations and plans to initiate a first-in-human phase 1 study in the first half of 2026.Meanwhile, in September 2025, Biovance Capital led a series A financing for the Portugal-based biotech company for an undisclosed amount, together with OrbiMed and Torrey Pines. TechnoPhageLocation: Lisbon Technologies: Bacteriophage therapies and antibody therapiesLead candidate: TP-102 for infections causing chronic ulcersTechnoPhage started off with a technology platform for the development of therapies based on bacteriophages – viruses that infect bacteria. Each bacteriophage kills a specific type of bacteria, making them much more precise than antibiotics, and they can kill drug-resistant bacteria, making them important alternatives to antibiotics. The company’s lead candidate, dubbed TP-102, is in phase 2 of development and is intended to treat infections causing chronic ulcers. Other products in the bacteriophage pipeline are targeting respiratory and urinary tract infections. Over the years, the company has expanded, and it now has platforms for neuroscience and ophthalmology indications. In neuroscience, the company has two different platforms: a biological one for the development of recombinant single domain antibody fragments (TA products), and a drug repositioning one using an in vivo model system for the screening of U.S. Food and Drug Administration (FDA) approved small molecules (TZ products).Meanwhile, in ophthalmology, TechnoPhage is also using its platform for the development of small domain antibodies in order to discover new, safer, and more effective antibodies, as well as a more practical administration route or delivery system. Biotech: A growing area within PortugalThe biotech industry has been on the rise in Portugal in recent years. From 2016 to 2020, the turnover of the more than 200 companies surveyed in the Portugal Biotech study more than tripled. Meanwhile, biotechnology ranks 5th in Portugal out of the 35 technological rankings regarding patent publications, with more than 80% of all patents published by Portuguese biotech companies taking place in the last decade.Portugal is also home to a specialized science and technology park called Biocant Park, in Cantanhede, which is where several of the companies on this list are located. The park aims to promote, develop, and apply advanced knowledge in life sciences, supporting business initiatives that have potential by providing an ecosystem that encompasses the entire innovation pipeline, from the creation of knowledge and advanced training, to the market, including technology transfer, financing, scientific dissemination, and industrial production.As BIO-Europe Spring is being hosted in the country’s capital in 2026, the hope is that this exposure will further help to drive Portugal’s biotech innovation, with more homegrown companies popping up in the coming years. This article was originally published in March 2019 and has since been updated by Willow Shah-Neville in March 2026.This article is reserved for subscribers Subscribe for free to continue reading.Enter your details to log in or subscribe. Email Company name Job title Continue Readingor Continue with Microsoft Continue with LinkedIn By continuing, I agree to receive Labiotech's newsletter and understand that my personal data will be processed according to the Privacy Policy. Partnering 2030: Biopharma Report 2025 Insights from 300+ biotechs and research institutes on partnering challenges, strategies, AI sentiment, and pharma partnering performance in 2025. Button CTA: Download the report Download the report Explore other topics: biotech startupFundingPartnershipsPortugal ADVERTISEMENT

Facts Only

Portugal's biotech ecosystem is growing, with a strong focus on medical biotech.
Bial is the largest pharmaceutical company in Portugal, headquartered in Porto.
BIO-Europe Spring is being held in Lisbon from March 23-25, 2026.
Beat Therapeutics, founded in 2023 in Porto, develops DDR inhibitors for pancreatic cancer.
BSIM Therapeutics, based in Coimbra, uses molecular modeling to develop transthyretin stabilizers for amyloidosis.
Exogenus Therapeutics, located in Cantanhede, focuses on exosome therapeutics, with Exo-101 for chronic wounds.
Immunethep, a University of Porto spin-off, develops vaccines and monoclonal antibodies targeting antibiotic-resistant bacteria.
Mondego Bio, also in Cantanhede, is developing PTPN2 inhibitors for cancer, with ZE00-0388 as its lead candidate.
TechnoPhage, based in Lisbon, works on bacteriophage therapies, with TP-102 in phase 2 for chronic ulcers.
Portugal's biotech turnover tripled from 2016 to 2020.
Biocant Park in Cantanhede supports biotech innovation with infrastructure and resources.
Several companies have secured funding and partnerships, including Exogenus with Boehringer Ingelheim and Lonza.

Executive Summary

Portugal's biotech sector is gaining momentum, with six innovative companies leading the charge in 2026. The industry is bolstered by the presence of Bial, the country's largest pharmaceutical company, and the hosting of BIO-Europe Spring in Lisbon, which highlights Portugal's growing credibility as a biotech hub. Key players include Beat Therapeutics, focusing on DDR inhibitors for pancreatic cancer; BSIM Therapeutics, developing transthyretin stabilizers for amyloidosis; and Exogenus Therapeutics, advancing exosome-based therapies for chronic wounds. Immunethep is tackling antibiotic resistance with vaccines and monoclonal antibodies, while Mondego Bio is working on PTPN2 inhibitors for cancer immunotherapy. TechnoPhage is pioneering bacteriophage therapies for chronic infections and expanding into neuroscience and ophthalmology. The sector's growth is supported by institutions like Biocant Park and increasing patent activity, with turnover tripling between 2016 and 2020. These developments suggest a promising trajectory for Portugal's biotech ecosystem, though challenges such as funding and scaling remain.

Full Take

The narrative presents Portugal's biotech sector as a rising star, leveraging academic spin-offs, strategic partnerships, and government support to carve a niche in precision medicine and infectious disease. The strongest version of this story highlights genuine innovation—Beat Therapeutics' DDR inhibitors, Immunethep's antibiotic resistance solutions, and Exogenus' exosome platform all address unmet medical needs with novel mechanisms. The hosting of BIO-Europe Spring in Lisbon serves as both validation and a catalyst, signaling Portugal's ambition to compete on the global stage.
However, the pattern scan reveals subtle elements of *ARC-0024 Ambiguity* in the framing of "steady rise" without quantifying challenges like talent retention or regulatory hurdles. The focus on preclinical successes and funding milestones, while impressive, risks *ARC-0043 Motte-and-Bailey*—celebrating early-stage promise while the "bailey" of commercial viability remains unproven. The repeated emphasis on academic origins and international partnerships could also hint at *ARC-0012 Borrowed Credibility*, where institutional prestige substitutes for market validation.
Root cause: This narrative echoes the broader European biotech playbook—small nations leveraging niche expertise and EU funding to punch above their weight. The unstated assumption is that innovation alone can overcome structural barriers like limited venture capital and fragmented healthcare systems. Historically, such ecosystems thrive when anchored by a single breakthrough (e.g., mRNA vaccines in Germany), but Portugal's diversified approach may dilute focus.
Implications: For human agency, this growth empowers local researchers and patients but risks overpromising if clinical translation stalls. The beneficiaries are clear—academics, early investors, and multinational partners—but the costs (e.g., brain drain if startups are acquired) are deferred. Second-order consequences include potential over-reliance on public funding, which may not scale with ambition.
Bridge questions: How does Portugal's biotech strategy compare to peers like Spain or Belgium in terms of risk tolerance and exit strategies? What metrics beyond funding rounds would indicate sustainable growth? Would a single high-profile failure (e.g., a phase 3 trial collapse) destabilize the ecosystem, or has it built resilience?
Counterstrike scan: A coordinated campaign would amplify success stories while downplaying attrition rates, using BIO-Europe Spring as a PR lever. The actual content aligns partially—it celebrates progress but acknowledges preclinical stages, avoiding outright hype. No red flags, but the tone leans optimistic without stress-testing the ecosystem's fragility.

Sentinel — Human

Confidence

The article shows strong signs of human authorship, with domain expertise, narrative passion, and specific attributions outweighing minor stylometric uniformity. No significant synthetic indicators detected.

Signals Detected

Moderate sentence length variance with some uniform rhythm, but includes idiosyncratic phrasing and domain-specific jargon typical of human expertise.

Balanced but not artificially so; includes passionate emphasis on Portugal's biotech growth and specific company narratives.

Some template-like structure (e.g., company profiles) but with unique details and varied attribution (e.g., specific funding sources, preclinical data).

Claims are well-attributed to named companies, investors, and events (e.g., BIO-Europe Spring, CARB-X funding). No obvious confabulation.

Human Indicators

Domain-specific expertise evident in detailed scientific explanations (e.g., DDR inhibitors, PTPN2 pathways).

Idiosyncratic emphasis on Portugal's biotech ecosystem and personal voice in framing the article's narrative.

Historical context (e.g., article updates, Biocant Park details) aligns with verifiable trends.